Jack Bendheim Sells 8,801 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 8,801 shares of the stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $44.47, for a total transaction of $391,380.47. Following the transaction, the chief executive officer directly owned 5,240 shares in the company, valued at $233,022.80. The trade was a 62.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Jack Bendheim also recently made the following trade(s):

• On Wednesday, November 12th, Jack Bendheim sold 21,536 shares of Phibro Animal Health stock. The shares were sold at an average price of $45.23, for a total value of $974,073.28.
• On Monday, November 10th, Jack Bendheim sold 38,303 shares of Phibro Animal Health stock. The stock was sold at an average price of $45.29, for a total value of $1,734,742.87.
• On Friday, November 7th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $42.86, for a total value of $150,867.20.
• On Tuesday, November 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $43.10, for a total value of $151,712.00.
• On Thursday, October 30th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.07, for a total value of $144,566.40.
• On Tuesday, October 28th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.56, for a total value of $146,291.20.
• On Thursday, October 23rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.18, for a total transaction of $141,433.60.
• On Wednesday, October 22nd, Jack Bendheim sold 11,859 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.27, for a total transaction of $477,561.93.
• On Monday, October 20th, Jack Bendheim sold 16,075 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.38, for a total transaction of $649,108.50.
• On Friday, October 17th, Jack Bendheim sold 700 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.03, for a total transaction of $28,021.00.

Phibro Animal Health Price Performance

Shares of NASDAQ:PAHC opened at $45.10 on Friday. The company has a quick ratio of 1.25, a current ratio of 2.76 and a debt-to-equity ratio of 2.46. Phibro Animal Health Corporation has a fifty-two week low of $16.16 and a fifty-two week high of $46.42. The firm has a 50-day simple moving average of $40.43 and a 200 day simple moving average of $31.80. The company has a market cap of $1.83 billion, a PE ratio of 38.22, a P/E/G ratio of 1.24 and a beta of 0.81.

Phibro Animal Health (NASDAQ:PAHC) last issued its earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.15. The firm had revenue of $363.89 million for the quarter, compared to analysts’ expectations of $345.44 million. Phibro Animal Health had a net margin of 3.73% and a return on equity of 32.14%. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. On average, sell-side analysts anticipate that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 17th. Investors of record on Wednesday, November 26th will be given a dividend of $0.12 per share. The ex-dividend date is Wednesday, November 26th. This represents a $0.48 dividend on an annualized basis and a yield of 1.1%. Phibro Animal Health’s payout ratio is currently 28.92%.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on PAHC shares. Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Tuesday. JPMorgan Chase & Co. boosted their price target on shares of Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Zacks Research cut shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Morgan Stanley set a $34.00 price objective on shares of Phibro Animal Health in a research report on Thursday, August 28th. Finally, Bank of America boosted their target price on shares of Phibro Animal Health from $19.00 to $27.00 and gave the company an “underperform” rating in a research note on Friday, August 29th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $31.40.

Institutional Investors Weigh In On Phibro Animal Health

Several institutional investors have recently bought and sold shares of the stock. Nuveen LLC acquired a new stake in Phibro Animal Health in the first quarter worth approximately $10,312,000. Capricorn Fund Managers Ltd bought a new stake in shares of Phibro Animal Health in the 3rd quarter worth $10,233,000. JPMorgan Chase & Co. raised its stake in shares of Phibro Animal Health by 1,730.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock worth $9,634,000 after buying an additional 225,110 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in shares of Phibro Animal Health in the third quarter valued at $8,931,000. Finally, Invesco Ltd. boosted its stake in Phibro Animal Health by 92.3% during the first quarter. Invesco Ltd. now owns 387,739 shares of the company’s stock valued at $8,282,000 after buying an additional 186,087 shares in the last quarter. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.